The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 26, 2022
Filed:
Oct. 25, 2018
Applicant:
Debiopharm International, S.a., Lausanne, CH;
Inventors:
Angela Romanelli, Lexington, MA (US);
Rodrigo R. Ruiz-Soto, Boston, MA (US);
Jose Ponte, Weymouth, MA (US);
Jutta Deckert, Lexington, MA (US);
Jan Pinkas, Belmont, MA (US);
Assignee:
Debiopharm International, S.A., Lausanne, CH;
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/02 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0019 (2013.01); A61K 47/6801 (2017.08); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61K 47/6867 (2017.08); A61P 35/02 (2018.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01);
Abstract
Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.